Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS3-007a in Pediatric Growth Hormone Deficiency
NCT07264595Phase 2Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Nov 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GS3-007 in growth hormone deficiency (GHD) (3 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events at 160 weeks and Annualized height velocity at 156 weeks. Started Jan 2026; status: recruiting.
02
Drugs
GS3-007
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT07264595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07264595.